Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma
18 Years
N/A
Both
Lymphoma
Trial Information
Phase II Trial of CC-5013 (Lenalidomide, Revlimid®) in Patients With Cutaneous T-Cell Lymphoma
OBJECTIVES:
Primary
- Determine the response rate and duration of response in patients with relapsed mycosis
fungoides/Sézary syndrome treated with lenalidomide.
- Determine the progression-free survival of patients treated with this drug.
Secondary
- Determine the toxicity of this drug in these patients.
- Correlate the antiangiogenetic and costimulatory effects of this drug with clinical
activity in skin biopsies from these patients.
- Assess the specific immune effector cell recruitment and augmentation of antitumor
response in these patients. (Northwestern University only)
OUTLINE: This is a multicenter study.
Patients receive oral lenalidomide once daily on days 1-21. Treatment repeats every 28 days
for 2 courses. Patients with progressive disease are removed from study. Patients achieving
complete response receive 2 additional courses of treatment beyond complete response.
Patients achieving partial response or stable disease may continue to receive lenalidomide
as above for up to 2 years. Treatment continues in the absence of disease progression or
unacceptable toxicity.
Patients undergo tissue biopsies at baseline and on day 1 of course 2. Tissue specimens are
analyzed for vessel density, presence of adhesion molecules, and immunophenotyping of dermal
infiltrate.*
NOTE: *At Northwestern University only, blood and tissue samples from 5-10 patients are
collected. Peripheral blood samples are analyzed for immune cell repertoire (CD4+, CD8+ T
cells, NK cells, NKT cells, CD4+, CD25+ T-regulatory cells, monocytes, and dendritic cell
subsets), cell surface molecules, and for TH1/TH2-associated cytokines, such as interleukin
(IL)-2, IL-4, IL-10, IL-12, interferon gamma, and tumor necrosis factor alpha, by flow
cytometry at baseline, day 15 of course 1, and at the end of course 1. Immunological
activation is assessed by analyzing surface expression of CD45RO and CTLA-4 on CD4+ and CD8+
T cells in blood and skin samples. Skin specimens are stored for future research studies on
predictive markers of lenalidomide activity.
After completion of study treatment, patients are followed every 3 months for 1 year.
PROJECTED ACCRUAL: A total of 35 patients will be accrued for this study.
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Histologically confirmed mycosis fungoides/Sézary syndrome
- Stage IA-IVB disease
- Must have failed ≥ 1 prior topical treatment, including any of the following:
- Steroids
- Nitrogen mustard
- Retinoids
- Phototherapy
- Photochemotherapy
- Radiotherapy
- Total skin electron beam
- Measurable disease with ≥ 1 indicator lesion designated prior to study entry
- Erythrodermic patients are eligible
PATIENT CHARACTERISTICS:
- ECOG performance status 0-2
- WBC ≥ 3,000/mm³
- ANC ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Creatinine ≤ 2.0 mg/dL
- Bilirubin ≤ 2.2 mg/dL
- AST and ALT ≤ 2 times upper limit of normal
- Not pregnant or nursing
- Negative pregnancy test
- Fertile women must use effective double-method contraception for ≥ 4 weeks before,
during, and for ≥ 4 weeks after completion of study therapy
- Fertile men must use effective contraception during and for ≥ 4 weeks after
completion of study therapy
- No other malignancy within the past 5 years except treated squamous cell and basal
cell carcinoma of the skin, carcinoma in situ of the cervix, or surgically removed
melanoma in situ of the skin (stage 0), with histologically confirmed free margins of
excision and no current evidence of disease
- No acute infection requiring systemic treatment
- No known allergic reaction or hypersensitivity to thalidomide
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- More than 4 weeks since prior topical therapy, systemic chemotherapy, or biological
therapy
- No prior stem cell transplantation
- No other concurrent systemic antipsoriatic or anticancer therapies, including
radiotherapy, thalidomide, or other investigational agents
- No other concurrent topical agents except emollients
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Response rate and duration of response
Outcome Time Frame:
After all patients have progressed
Safety Issue:
No
Principal Investigator
Timothy M. Kuzel, MD
Investigator Role:
Study Chair
Investigator Affiliation:
Robert H. Lurie Cancer Center
Authority:
United States: Food and Drug Administration
Study ID:
NU 04H5
NCT ID:
NCT00466921
Start Date:
February 2005
Completion Date:
February 2014
Related Keywords:
- Lymphoma
- recurrent mycosis fungoides/Sezary syndrome
- stage I mycosis fungoides/Sezary syndrome
- stage II mycosis fungoides/Sezary syndrome
- stage III mycosis fungoides/Sezary syndrome
- stage IV mycosis fungoides/Sezary syndrome
- Lymphoma
- Mycosis Fungoides
- Sezary Syndrome
- Lymphoma, T-Cell, Cutaneous
Name | Location |
|---|---|
| M. D. Anderson Cancer Center at University of Texas | Houston, Texas 77030-4009 |
| Robert H. Lurie Comprehensive Cancer Center at Northwestern University | Chicago, Illinois 60611 |
| Stanford Cancer Center | Stanford, California 94305-5824 |
